1. What Is the Insomnia Drug Market?
The Insomnia Drug Market covers the hypnotic medicines used to treat the chronic insomnia disorder that affects 10 to 15 percent of adults with the significant daytime impairment that the sleep disturbance creates. The market encompasses the GABA-A positive allosteric modulator benzodiazepines and the non-benzodiazepine Z-drugs including zolpidem, eszopiclone, and zaleplon. The dual orexin receptor antagonists suvorexant, lemborexant, and daridorexant, the melatonin receptor agonist ramelteon, and the low-dose doxepin for the sleep maintenance insomnia complete the treatment classes. Insomnia drug development has transitioned from the GABA-A modulation that the traditional hypnotics including the benzodiazepines and the Z-drugs use. The traditional hypnotics carry the dependence, the tolerance, the rebound insomnia, and the next-day cognitive impairment concerns that limit the chronic use. The orexin receptor antagonism that the DORA mechanism provides blocks the wakefulness-promoting orexin neuropeptide without the GABA-A sedation that the traditional hypnotics produce. The insomnia market is advancing with the daridorexant Phase III STARS 1 and 2 trials demonstrating the superior wake after sleep onset and sleep onset latency improvement versus placebo. The improvement appeared at the 25 and 50 mg doses. The preserved subjective next-day alertness that the orexin mechanism achieves contrasts with the residual sedation that the traditional hypnotics create.
2. Insomnia Drug Market Size & Forecast
3. Emerging Technologies
- Dual orexin receptor antagonist DORA mechanism of action blocks the OX1R and OX2R receptors that the wakefulness-promoting orexin A and orexin B neuropeptides stimulate to maintain the wakefulness state. The blockade prevents the orexin drive to the wake-promoting brainstem nuclei without activating the GABA-A receptor. The elderly insomnia patient who falls at night is most vulnerable to the next-day sedation, the memory impairment, and the motor incoordination that the traditional hypnotic creates.
- Daridorexant Quviviq STARS 1 and 2 Phase III trials demonstrated 22 to 29 fewer minutes of wake after sleep onset at the 50 mg dose versus placebo. The trials also showed 22 to 28 fewer minutes of latency to sleep onset. The improvement came without the next-day residual sedation. The suvorexant 20 mg and the lemborexant 10 mg Phase III data show the residual sedation at their approved doses. The daridorexant achieves the sleep maintenance and onset improvement plus the preserved daytime alertness that the prescriber seeks for the chronic insomnia patient.
- Cognitive-behavioural therapy for insomnia CBT-I is the first-line treatment that the American College of Physicians and the sleep medicine guidelines recommend above the pharmacological treatment. The therapy provides the sleep restriction, the stimulus control, the sleep hygiene, and the cognitive restructuring. The approach addresses the perpetuating factors of the chronic insomnia that the hypnotic medication does not treat. The pharmacological treatment alone does not resolve the insomnia after discontinuation.
- Zolpidem gender difference in the dose requirement arises from the FDA 2013 recommendation to halve the zolpidem dose for women based on the pharmacokinetic data. The data demonstrated the 45 percent higher peak plasma concentration in women for the same dose. The higher concentration creates the next-day driving impairment that the FDA analysis of the NTSB accident data identified as the driving-related safety signal.
Similar technologies are also transforming adjacent markets. Learn more in our Narcolepsy Drug Market.
4. Key Market Opportunity
Within the Insomnia Drug market, a leading opportunity is DORA market displacement of Z-drug prescribing, where the improved safety profile and tolerability of orexin antagonists supports prescribing transitions from Z-drugs in chronic insomnia management. Companies with approved DORA agents capture this safety-driven prescribing transition. A separate growth lever stems from DORA expansion into circadian and shift work sleep disorders. As DORA Z-drug displacement proceeds and indication expansion advances, the addressable opportunity is evolving from Z-drug-dominated insomnia treatment toward DORA-based safer chronic insomnia pharmacotherapy.
5. Top Companies in the Insomnia Drug Market
The following organisations hold leading positions in the Insomnia Drug Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Merck
- Eisai
- Idorsia Pharmaceuticals
- Sanofi
- Pfizer
- Sun Pharma
- Cipla
- Sumitomo Pharma
- Vanda Pharmaceuticals
- Currax Pharmaceuticals
6. Market Segmentation
The Insomnia Drug Market is analysed across 3 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Drug Class | DORAZ-DrugMelatonin AgonistAntidepressant HypnoticAntihistamine OTC |
| By Indication | Sleep OnsetSleep MaintenanceBoth |
| By Geography | North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Insomnia Drug Market trajectory over the forecast period:
DORA Mechanism Blocking Orexin Wakefulness Drive Without GABA-A Receptor Activation Has Provided the Hypnotic Without the Next-Day Sedation, Memory Impairment, and Motor Incoordination That Benzodiazepines and Z-Drugs Create for the Elderly Insomnia Patient Most Vulnerable to Night Falls.Merck's suvorexant Belsomra, Eisai's lemborexant Dayvigo, and Idorsia Pharmaceuticals's daridorexant Quviviq have collectively demonstrated superiority to placebo across sleep-onset and sleep-maintenance outcomes without the hangover sedation, dependency, and withdrawal liability of benzodiazepines and z-drugs. The orexin receptor blockade mechanism selectively reduces wakefulness-promoting orexin signalling without producing the broad CNS depression of GABA-targeting hypnotics, enabling sleep onset and maintenance without the residual psychomotor impairment that restricts morning activities and driving in elderly patients receiving benzodiazepine sleep therapy. APA and AASM insomnia guideline updates reflecting the DORA class's safety profile have repositioned benzodiazepines and z-drugs as second-line agents reserved for patients who fail DORA therapy, a guideline shift that is gradually transforming prescribing patterns across psychiatry and primary care.
Daridorexant Quviviq 22 to 29 Fewer Minutes WASO and SOL at 50 mg Versus Placebo With Preserved Daytime Alertness Has Established the DORA With the Combined Sleep Maintenance, Sleep Onset, and Daytime Function Profile That Chronic Insomnia Pharmacotherapy Requires.Eisai's lemborexant demonstrated significantly faster sleep onset, fewer awakenings, and superior Subjective Sleep Quality compared to zolpidem ER in SUNRISE 2, and the Clinical Global Impression of improvement for lemborexant was statistically superior to z-drug comparator in elderly patients where residual sedation from benzodiazepines causes fall and cognitive risks. The pharmacokinetic design of lemborexant at a half-life of 17-19 hours achieves sleep maintenance without morning residual sedation that characterises zolpidem's longer and more variable elimination half-life in elderly metabolisers with reduced CYP3A4 capacity. Real-world pharmacy claims data showing increasing lemborexant market share at the expense of z-drugs among psychiatrists and sleep medicine specialists validates the clinical trial differentiation strategy that Eisai pursued in SUNRISE-2 with a head-to-head design versus the most widely prescribed generic z-drug.
CBT-I First-Line Insomnia Treatment Above Pharmacological Therapy Addressing Sleep Restriction, Stimulus Control, and Cognitive Restructuring of the Perpetuating Factors That Hypnotic Medication Does Not Treat Has Established the Behaviour Therapy as the Curative Approach That Medication Supplements.Somryst and Sleepio CBT-I digital therapeutics have demonstrated 66-80% improvement in sleep efficiency and 25-40% reduction in insomnia severity index scores in randomised trials, providing evidence-based psychological treatment for chronic insomnia that outperforms placebo and demonstrates sustained benefit at 6-month follow-up without the dependency risks of pharmacotherapy. The sleep-restriction, stimulus-control, and sleep-hygiene components of CBT-I delivered through app-based programmes enable therapist-independent administration that addresses the chronic therapist shortage preventing access to the 30-40 sessions of in-person CBT-I that traditional delivery requires. Prescription CBT-I digital therapeutics from Pear Therapeutics and similar platforms are establishing payer coverage through value-based contracts where insomnia-related healthcare utilisation reduction provides the economic justification for reimbursement of digital therapeutic subscriptions.
For related market intelligence, see the Neurology Drug Market.
8. Segmental Analysis
By drug class, the dual orexin receptor antagonist segment dominated the Insomnia Drug Market in 2025, as Merck's Belsomra, Eisai's Dayvigo, and Idorsia Pharmaceuticals's Quviviq displaced older hypnotics through favourable safety and dependence profiles, generating the fastest-growing branded share of the indication.
By indication, the chronic insomnia segment is projected to register the highest growth rate through 2034, as orexin antagonists expand among long-term users seeking alternatives to benzodiazepines and z-drugs whose dependence risk limits sustained use.
9. Regional Analysis
Regional demand patterns across the Insomnia Drug Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Insomnia Drug Market in 2025, accounting for approximately 42% of global revenue, due to US premium pricing for DORA agents and Z-drugs and the large insomnia diagnosed patient population. Moreover, DORA adoption and Z-drug displacement are most advanced in US sleep medicine. In addition, low-dose doxepin and melatonin agonist use sustains demand. Regional dominance is attributed to this combination of pricing environment and DORA adoption.
Highest CAGR Region
Asia Pacific is projected to register the highest CAGR in the Insomnia Drug Market through 2034, driven by expanding insomnia diagnosis and pharmacotherapy access in China, Japan, and South Korea and the large insomnia patient population. The region is also witnessing DORA adoption growing. Moreover, generic Z-drug access sustains baseline insomnia treatment. The combination of these demand drivers and patient scale positions Asia Pacific for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Insomnia Drug Market was valued at USD 5.44 Bn in 2025 and is projected to reach USD 9.83 Bn by 2034, growing at a CAGR of 6.8% over the 2026–2034 forecast period.
The Insomnia Drug Market is projected to grow at a CAGR of 6.8% from 2026 to 2034.
North America dominated the Insomnia Drug Market in 2025, accounting for approximately 42% of global revenue, due to US premium pricing for DORA agents and Z-drugs and the large insomnia diagnosed patient population.
The leading companies in the Insomnia Drug Market include Merck, Eisai, Idorsia Pharmaceuticals, Sanofi, Pfizer, Sun Pharma, Cipla, Sumitomo Pharma, Vanda Pharmaceuticals, Currax Pharmaceuticals.
Dora mechanism blocking orexin wakefulness drive without gaba-a receptor activation has provided the hypnotic without the next-day sedation, memory impairment, and motor incoordination that benzodiazepines and z-drugs create for the elderly insomnia patient most vulnerable to night falls.
By drug class, the dual orexin receptor antagonist segment dominated the Insomnia Drug Market in 2025, as Merck's Belsomra, Eisai's Dayvigo, and Idorsia Pharmaceuticals's Quviviq displaced older hypnotics through favourable safety and dependence profiles, generating the fastest-growing branded share of the indication.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.